<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914628</url>
  </required_header>
  <id_info>
    <org_study_id>TK008</org_study_id>
    <secondary_id>2009-012973-37</secondary_id>
    <nct_id>NCT00914628</nct_id>
  </id_info>
  <brief_title>TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia</brief_title>
  <official_title>TK008 Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MolMed S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MolMed S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this randomized trial is to compare disease-free survival (DFS) in high
      risk leukemia patients who underwent haploidentical HCT followed by an add back strategy of
      HSV-Tk donor lymphocytes or standard haploidentical HCT
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delayed immune-reconstitution remains one of the main limitation of haploidentical stem cell
      transplantation. The risk of severe infections remains high for several months and CD3+
      reconstitution could take more than 10 months. The low number of lymphocytes infused with the
      graft, the degree of HLA (Human Leukocyte Antigen) disparity, and a reduced thymic function
      in adults and differences in host/donor antigen presenting cells are contributing causes.

      The infusions of HSV-TK engineered lymphocytes may represent a significant therapeutic
      improvement in haploidentical HCT (hematopoietic cell transplantation), because it remarkably
      may enhance both GvL (Graft versus Leukemia) activity, thus reducing the occurrence of
      disease relapse, and post-transplant immune reconstitution in the absence of chronic immune
      suppression, thus decreasing the rate of both post-transplant opportunistic infections and
      transplant-related mortality. Furthermore, the efficient control of GvHD achieved via the
      suicide mechanism allows also the multiple infusion of HSV-TK-treated donor lymphocytes, when
      needed, that might further improve post-transplant host immune reconstitution, and survival
      in patients receiving haplo-HCT. Finally, this therapeutic approach can become a valuable
      option for all candidates, including patients with advanced disease and older age.

      The proposed clinical trial represents an innovative therapeutic treatment for patients
      affected by high risk acute leukemia, who have undergone haploidentical stem cell
      transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>From the date of randomization to the date of the first occurrence of relapse (or progression) or death, whichever came first, assessed up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of randomization to the date of death, assessed up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immuno reconstitution (IR)</measure>
    <time_frame>Weekly up to IR after engraftment of HCT, monthly for 6 months from date of IR and then at month 9 and 12</time_frame>
    <description>Defined as the time to reach a level of circulating CD3+ ≥ 100/µl for two consecutive observations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment rate</measure>
    <time_frame>Weekly up to IR after HCT, monthly for 6 months after IR and then at month 9 and 12</time_frame>
    <description>Defined as the persistent blood cells count at a predefined level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade 2, 3, or 4 acute GVHD (aGvHD)</measure>
    <time_frame>From the date of HCT until the date of the first occurrence of aGvHD, assessed up to 6 months</time_frame>
    <description>Diagnosed and graded according to standard criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of extensive chronic GvHD (cGvHD)</measure>
    <time_frame>From the date of HCT until the date of the first occurrence of cGvHD, assessed up to 12 months</time_frame>
    <description>Diagnosed and graded according to standard NIH consensus criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR)</measure>
    <time_frame>From the date of randomization to the date of the first occurrence of relapse, assessed up to 12 months</time_frame>
    <description>Defined on the basis of morphologic evidence of leukaemia in bone marrow or other sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of infectious episodes and infectious disease mortality</measure>
    <time_frame>From randomization to the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the acute and long-term toxicity related to the HSV-Tk infusions</measure>
    <time_frame>From HSV-Tk infusions to death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) and Medical Care Utilization (MCU) in both arms</measure>
    <time_frame>From randomization to end of study</time_frame>
    <description>Medical resource use data collected will be used in health economic analyses where it may be combined with other data from other sources such as cost data or other clinical parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>From the date of randomization to the date of death, assessed up to 12 months</time_frame>
    <description>Defined for all patients as any death without previous occurrence of a documented relapse (or progression)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Acute Leukemia (Category)</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV-TK engineering donor Lymphocytes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T-cell depleted or T-cell replete strategies</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>HSV-Tk</intervention_name>
    <description>Infusion of genetically modified lymphocytes 1x10^7 c/kg: first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>T-cell depleted or T-cell replete strategies</intervention_name>
    <description>Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years with HCT comorbidity index &lt; 3

          -  Any of the following conditions:

               -  AML and ALL in 1st complete remission (CR) at high risk of relapse based on
                  negative prognostic factors (for the definition of high-risk of relapse see
                  Appendix H).

               -  AML and ALL in 2nd or subsequent CR

               -  Secondary AML in CR

               -  secondary AML and ALL in 1st or 2nd relapse or primary refractory

          -  Absence of timely and suitable fully HLA matched or one HLA locus mismatched family or
             unrelated donor and, at Investigator's discretion, absence of other possible
             therapeutic alternatives

          -  Stable clinical conditions and life expectancy &gt; 3 months

          -  PS ECOG &lt; 2

          -  Patients, or legal guardians, and donors must sign an informed consent indicating that
             they are aware this is a research study and have been told of its possible benefits
             and toxic side effects

          -  Serum creatinine &lt; 1.5 x ULN

          -  Bilirubin &lt; 1.5 x ULN; transaminases &lt; 3 x ULN

          -  Left ventricular ejection fraction &gt; 45%

          -  QTc interval &lt; 450 ms

          -  DLCO &gt; 50%

        Exclusion Criteria:

          -  Patients with life-threatening condition or complication other than their basic
             condition

          -  Contraindication to haploidentical HCT as defined by the Investigator

          -  Patients with active CNS disease

          -  Pregnant or lactation.

        Exclusion criteria for HSV-Tk infusion:

          -  Infections requiring administration of ganciclovir, valganciclovir or acyclovir at the
             time of infusion: HSV-Tk cells can be administered after a 24-hour discontinuation
             interval of antiviral therapy

          -  GvHD requiring systemic immunosuppressive therapy

          -  Ongoing systemic immunosuppressive therapy after haploidentical HCT

          -  Administration of G-CSF after haploidentical HCT

          -  CD3+ cells ≥ 100/µl at day of planned experimental infusion after haploidentical HCT

          -  Any grade 3-4 adverse event related to HSV-Tk infusion or a grade 2 adverse event that
             does not resolve to no more than grade 1 before the next infusion

        For criteria 2, 3 and 4: HSV-Tk cells can be administered after an adequate patient
        wash-out period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Ciceri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Ciceri, MD</last_name>
    <phone>0</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayesh Mehta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jayesh Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rizwan Romee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rizwan Romee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Donato, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michele Donato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Maertens, MD</last_name>
    </contact>
    <investigator>
      <last_name>Johan Maertens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Deconinck, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Deconinck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charitè; Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Uharek, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lutz Uharek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnold Ganser, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Eva Mischak-Weissinger, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Arnold Ganser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Mischak-Weissinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dietger Niederwieser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Bethge, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wolfgang Bethge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Bunjes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Donald Bunjes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Papanicolaou Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelia Yannaki, MD</last_name>
    </contact>
    <investigator>
      <last_name>Evangelia Yannaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnon Nagler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arnon Nagler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Ciceri, MD</last_name>
      <phone>0</phone>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Narni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Franco Narni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Rodríguez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mercedes Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high risk acute leukemia</keyword>
  <keyword>HSV-TK</keyword>
  <keyword>Haploidentical HCT</keyword>
  <keyword>GvHD</keyword>
  <keyword>GvL</keyword>
  <keyword>Immunoreconstitution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No, only information requested by law will be released</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

